Yazar "Demirci, U." seçeneğine göre listele
Listeleniyor 1 - 8 / 8
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe EFFECTS OF EXCERCISE TRAINING ON PHYSICAL ACTIVITY IN ADULT SEVERE HEMOPHILIA A PATIENTS(Wiley, 2023) Demirci, U.; Umit, E.; Ozdemir, H.; Tuna, F.; Kabayel, D.; Demir, A. M.[Abstract Not Available]Öğe The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey(Oxford Univ Press, 2018) Kilickap, S.; Olmez, O. F.; Cicin, I.; Demirci, U.; Alan, O.; Cabuk, D.; Sakalar, T.[Abstract Not Available]Öğe EVALUATION OF SARCOPENIA WITH HANDGRIP STRENGTH IN ADULT PATIENTS WITH CONGENITAL HEMOPHILIA(Wiley, 2020) Umit, E. G.; Bas, V.; Demirci, U.; Ekici, B.; Demir, A. M.[Abstract Not Available]Öğe GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients [Meeting Abstract](Elsevier Science Inc, 2021) Peled, N.; Gillis, R.; Kilickap, S.; Froesch, P.; Orlov, S.; Filippova, E.; Demirci, U.[Abstract Not Available]Öğe Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?(Oxford Univ Press, 2019) Kilickap, S.; Basal, F. Bugdayci; Demirkazik, A.; Gursoy, P.; Demirci, U.; Erman, M.; Yumuk, F.[Abstract Not Available]Öğe LONGTERM OUTCOMES OF PHARMACOKINETIC BASED INDIVIDUALIZED PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS(Wiley, 2023) Demir, A. M.; Demirci, U.; Umit, E. G.[Abstract Not Available]Öğe Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey(Elsevier Science Inc, 2019) Kilickap, S.; Demirci, U.; Bugdayci, F.; Tural, D.; Korkmaz, T.; Paydas, S.; Yilmaz, C.[Abstract Not Available]Öğe The Utility of CONUT Score in Diffuse Large B Cell Lymphoma Patients(Wolters Kluwer Medknow Publications, 2021) Baysal, M.; Bas, V; Demirci, U.; Gulsaran, S. K.; Umit, E.; Kirkizlar, H. O.; Demir, A. M.Background: Assessment of nutritional status is gaining more importance in cancer patients because nutritional status is associated with response to chemotherapy, side effects of cancer treatment and disease progression. Several studies that were performed on patients with solid malignancies have shown the clinical significance of CONUT score (Controlling nutritional status). Aims: Therefore we tried to show the utility of CONUT score in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients which is the most frequently seen B Cell Lymphoma type. Methods: Data of the 81 patients diagnosed with DLBCL were retrospectively evaluated. The primary endpoint of our study was to evaluate and classify newly diagnosed DLBCL patients according to the CONUT score and secondary endpoint was to show any relationship with CONUT score and overall survival. Patients' demographics, treatment details, stages, extranodal involvements, the presence of bulky disease, response to treatment options and overall survivals were evaluated from medical recordings. Results: Univariate cox regression analysis CONUT score was associated with overall survival (HR: 2.34-95% CI: 1.55-3.24 P = 0.040). On multivariate Cox regression analysis model CONUT score >= 5 was found to be an independent prognostic factor for overall survival (HR: 4.96-95% CI: 1.77-13.97- P = 0.002). Conclusion: The value of obtaining nutritional status in cancer patients is underestimated and CONUT score is simple, easily applicable and in our opinion is going to fill the gap especially in DLBCL patients.
